Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)
T. Ziemssen,A. D. Bass,R. Berkovich,S. Eichau,J. Hobart,S. F. Hunter,V. Limmroth,D. Pelletier,C. Pozzilli,S. Schippling, B. A. Singer,L. Sousa, A. Traboulsee, B. M. J. Uittlehaag,B. Van Wijmeersch, E. M. Poole,Z. Choudhry,S. Geertsen,N. Daizadeh, G. Comi EUROPEAN JOURNAL OF NEUROLOGY（2020）
AI 理解论文
溯源树
样例
